E-ISSN 2602-3164
EJMI. 2023; 7(4): 378-383 | DOI: 10.14744/ejmi.2023.50258

Hyperkalemia and Use of RAAS Inhibitors in Stage 3-5 Chronic Kidney Disease Non-Dialysis Patients: A Single-Center Experience

Cebrail Karaca1, Seyda Gul Ozcan2
1Division of Nephrology, Department of Internal Medicine, Van Yuzuncu Yil University Faculty of Medicine, Van, Türkiye, 2Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University- Cerrahpasa, Istanbul, Türkiye

Objectives: Despite the risk of hyperkalemia, renin angiotensin aldosterone system inhibitors (RAASi) are widely used in chronic kidney disease (CKD) because of their positive effects on mortality. In this study, we aimed to investigate the frequency of hyperkalemia, the use of RAASi, and potassium binders in Stage 3-5 CKD non-dialysis patients. Methods: In this cross-sectional study, non-dialysis patients with Stage 3-5 CKD were recruited and evaluated at two visits with a 3-month interval. The use of RAASi and potassium-lowering therapy of the patients were followed up. Presence of hyperkalemia at both visits was defined as persistent hyperkalemia. Results: A total of 182 patients were included in the study. The mean serum potassium was 4.8±0.5 mmol/L, and the prevalence of hyperkalemia was 27.5%. Serum potassium level was similar between CKD groups. RAASi use was significantly higher in CKD Stages 3a and 3b than the other groups (p<0.001). Potassium binder use was highest in CKD Stage 5. Despite persistent hyperkalemia, most of the patients continued to use the RAASi. Potassium binder use was also high to tolerate hyperkalemia. Conclusion: Our study reveals that RAASi continues to be used in daily practice even in cases of persistent hyperkalemia due to its positive effects. Keywords: Chronic kidney disease, hyperkalemia, renin angiotensin aldosterone system inhibitors, potassium binder, persistent hyperkalemia.


Cite This Article

Karaca C, Ozcan S. Hyperkalemia and Use of RAAS Inhibitors in Stage 3-5 Chronic Kidney Disease Non-Dialysis Patients: A Single-Center Experience. EJMI. 2023; 7(4): 378-383

Corresponding Author: Cebrail Karaca

Full Text PDF PDF Download
EJMI & EJMI